• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVOCURE GMBH OPTUNE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVOCURE GMBH OPTUNE Back to Search Results
Model Number TFH9100
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Post Operative Wound Infection (2446)
Event Date 10/20/2019
Event Type  Injury  
Manufacturer Narrative
Novocure's opinion is that a contribution of the array placement to the event cannot be ruled out.Contributing factors for wound infection in this patient also include, prior radiation, chemotherapy, and prior surgery affecting skin integrity.Wound infection is an expected event with device use and was reported as an adverse event in the ef-14 trial of optune together with temozolomide (tmz) compared to tmz alone in patients with newly diagnosed gbm in both arms of the trial (<1% and <1% in optune/tmz and tmz arms respectively).
 
Event Description
A (b)(6) female patient with newly diagnosed glioblastoma began optune therapy on (b)(6) 2018, as part of the ist "spare-scalp preservation and radiation plus alternating electric tumor treatment field (novottf-200a, optune) for patients with glioblastoma: a pilot study".On october 21, 2019, novocure was informed that the patient had developed a skin irritation on the scalp and applied topical steroid (clobetasol) and nonsteroidal (tetrix) creams to the affected area.Optune therapy was temporarily discontinued.The patient subsequently developed a pruritic pus filled area on the surgical resection site (last resection (b)(6) 2018).Prescribing physician was informed and started patient on a 14 day antibiotic course, however, the infection worsened.On an unspecified date, patient was hospitalized and underwent wound revision surgery.Optune therapy was permanently discontinued.Prescribing physician was contacted for additional information and causality assessment with no response.
 
Manufacturer Narrative
On december 23, 2021, novocure discovered that the initial submitted medical device report had a typo in the model number for the optune device in section d4-suspect medical device model number.Corrected model number is tfh9100.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTUNE
Type of Device
OPTUNE
Manufacturer (Section D)
NOVOCURE GMBH
business village d4
park 6/platz 10
root d4, NH 6039
SZ  6039
Manufacturer (Section G)
NOVOCURE GMBH
business village d4
park 6/platz 10
root d4, NH 6039
SZ   6039
Manufacturer Contact
sharon perez
195 commerce way
portsmouth, NH 03801
2077527602
MDR Report Key9334691
MDR Text Key166779713
Report Number3009453079-2019-00128
Device Sequence Number1
Product Code NZK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P100034
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 01/11/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Model NumberTFH9100
Device Catalogue NumberN/A
Device Lot NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Device Age2 YR
Initial Date Manufacturer Received 10/20/2019
Initial Date FDA Received11/18/2019
Supplement Dates Manufacturer Received12/23/2021
Supplement Dates FDA Received01/11/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured10/02/2017
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
CLOBETASOL.; DEXAMETHASONE.; LEVETIRACETAM.; LEVOTHYROXINE.; LORATADINE.; MONETLUKAST.; ONDANSETRON.; SIMVASTATIN.; TEMOZOLOMIDE.; CLOBETASOL; DEXAMETHASONE; LEVETIRACETAM; LEVOTHYROXINE; LORATADINE; MONETLUKAST; ONDANSETRON; SIMVASTATIN; TEMOZOLOMIDE
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age60 YR
Patient SexFemale
Patient Weight81 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-